Fig. 4
SJP-L-5 specifically inhibits HIV-1 at the pre-integration stage. a 293 T cells were infected with VSV-G pseudotyped HIV-1-Luc or MLV-Luc in the presence of SJP-L-5 (5 μg/ml, Gray) or DMSO (Black) as a negative control. The antiretroviral activity was evaluated by testing the activity of the luciferase reporter gene at 48 h post infection. Error bars indicate standard deviations of triplicate values. Statistical significance was analyzed by the Student’s t test. ** P < 0.01 versus the negative control. b 293 T cells were infected with VSV-G pseudotyped HIV-1-GFP, in the presence of SJP-L-5 (0, 1.25, 5, or 20 μg/ml), or DMSO as a negative control; AZT (10 μM) was used as a positive control. 24 h after infection, infectivity was analyzed with a fluorescence microscope. c 293 T cells were transfected with 0.1 μg of pNL4-3luc in the presence of SJP-L-5 (5 μg/ml, (Gray)) or DMSO (Black) as a negative control. 48 h later, cellular luciferase activity was determined. d The antiviral activity of SJP-L-5 was tested using H9/HIV-1IIIB cells, and EC50s were greater than 200 μg/ml. The inhibition was calculated as the p24 levels in control cells divided by that in SJP-L-5 treated cells